221 CRESCENT STREET, WALTHAM, MA
Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072
Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
News, Material Contracts
Reports First Quarter 2026 Financial Results and Provides Corporate Update
Spyre Therapeutics Enters Underwriting Agreement for $62.00 Share Offering
Spyre Therapeutics Reports $741 Million Cash as of March 31, 2026
Q2
Q1
FY 2024
Q3
Amended Annual Report
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities to be Offered to Employees
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
PRER14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Post-Effective Amendment to Registration Statement
Submission Upload
Correspondence